FDA committee scheduled to review compounder access for seven peptide substances

The FDA Pharmacy Compounding Advisory Committee has scheduled a meeting for July 23 and July 24, 2026, to evaluate seven peptide-related bulk drug substances for potential inclusion on the Section 503A Bulk Drug Substances List. This review will determine whether compounding pharmacies can continue to legally prepare these substances for clinic use.

During the two-day session, the committee will review detailed safety, effectiveness, and characterization data. On July 23, 2026, the focus will be on BPC-157, KPV, TB-500, and MOTS-c, including both their free base and acetate forms. The following day, July 24, 2026, the committee will turn its attention to Emideltide, Semax, and Epitalon.

For medical-aesthetic practices utilizing these peptides in wellness, anti-aging, or healing protocols, this meeting represents a critical regulatory milestone. If the committee recommends against including these peptides on the 503A list, the FDA is highly likely to restrict compounding pharmacies from sourcing and distributing them. Clinicians currently offering these therapies should monitor the upcoming July 2026 rulings to prepare for potential supply disruptions or the need to transition patients to alternative, approved treatment options.

Source: U.S. FDA, https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-materials-pharmacy-compounding-advisory-committee